[{"id":"4a7a80ea-21b3-4d81-8f03-943129f3e58b","acronym":"KURRENT-HN","url":"https://clinicaltrials.gov/study/NCT04997902","created_at":"2021-08-10T14:52:48.661Z","updated_at":"2024-07-02T16:35:31.801Z","phase":"Phase 1/2","brief_title":"Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)","source_id_and_acronym":"NCT04997902 - KURRENT-HN","lead_sponsor":"Kura Oncology, Inc.","biomarkers":" PIK3CA • HRAS","pipe":"","alterations":" ","tags":["PIK3CA • HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Piqray (alpelisib) • Zarnestra (tipifarnib)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 12/07/2021","start_date":" 12/07/2021","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2023-10-25"},{"id":"1eb7a494-8bc2-4917-8b85-cf6852752fd9","acronym":"GLORIA","url":"https://clinicaltrials.gov/study/NCT04121455","created_at":"2021-03-03T18:53:40.301Z","updated_at":"2024-07-02T16:35:45.144Z","phase":"Phase 1/2","brief_title":"Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients","source_id_and_acronym":"NCT04121455 - GLORIA","lead_sponsor":"TME Pharma AG","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 mutation","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Avastin (bevacizumab) • olaptesed pegol (NOX-A12)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 09/12/2019","start_date":" 09/12/2019","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-06-22"},{"id":"97348d3c-50dc-4afa-b18a-6e0c3e18c9b6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05693090","created_at":"2023-01-20T14:59:55.661Z","updated_at":"2024-07-02T16:35:54.005Z","phase":"Phase 1","brief_title":"Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05693090","lead_sponsor":"Kura Oncology, Inc.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Zarnestra (tipifarnib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 02/01/2023","start_date":" 02/01/2023","primary_txt":" Primary completion: 07/27/2027","primary_completion_date":" 07/27/2027","study_txt":" Completion: 07/27/2027","study_completion_date":" 07/27/2027","last_update_posted":"2023-03-06"},{"id":"eedda5a0-ec8c-4127-bb15-acd6b4c60d96","acronym":"SEQ-HN","url":"https://clinicaltrials.gov/study/NCT03719690","created_at":"2021-01-18T18:13:51.350Z","updated_at":"2024-07-02T16:36:00.691Z","phase":"Phase 2","brief_title":"Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy","source_id_and_acronym":"NCT03719690 - SEQ-HN","lead_sponsor":"Kura Oncology, Inc.","biomarkers":" HRAS","pipe":" | ","alterations":" RAS wild-type • HRAS mutation • HRAS wild-type","tags":["HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS wild-type • HRAS mutation • HRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zarnestra (tipifarnib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 284","initiation":"Initiation: 11/05/2018","start_date":" 11/05/2018","primary_txt":" Primary completion: 05/30/2023","primary_completion_date":" 05/30/2023","study_txt":" Completion: 05/31/2023","study_completion_date":" 05/31/2023","last_update_posted":"2022-11-09"},{"id":"71f1c969-b84a-461e-abff-6a5fd7a94ebc","acronym":"","url":"https://clinicaltrials.gov/study/NCT02535650","created_at":"2021-01-17T17:10:25.985Z","updated_at":"2024-07-02T16:36:15.904Z","phase":"Phase 2","brief_title":"Study of Tipifarnib in Patients With Previously-Treated, Advanced, HRAS Mutant Urothelial Carcinoma","source_id_and_acronym":"NCT02535650","lead_sponsor":"Samsung Medical Center","biomarkers":" STK11 • HRAS","pipe":" | ","alterations":" STK11 mutation • HRAS mutation","tags":["STK11 • HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e STK11 mutation • HRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zarnestra (tipifarnib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 19","initiation":"Initiation: 11/12/2015","start_date":" 11/12/2015","primary_txt":" Primary completion: 03/01/2022","primary_completion_date":" 03/01/2022","study_txt":" Completion: 06/01/2022","study_completion_date":" 06/01/2022","last_update_posted":"2022-03-08"},{"id":"05393640-65bf-4e1a-874e-2d7c1305fa9f","acronym":"KO-TIP-001","url":"https://clinicaltrials.gov/study/NCT02383927","created_at":"2021-01-17T17:10:25.340Z","updated_at":"2024-07-02T16:36:30.260Z","phase":"Phase 2","brief_title":"Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations","source_id_and_acronym":"NCT02383927 - KO-TIP-001","lead_sponsor":"Kura Oncology, Inc.","biomarkers":" HRAS","pipe":" | ","alterations":" HRAS mutation","tags":["HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zarnestra (tipifarnib)"],"overall_status":"Completed","enrollment":" Enrollment 63","initiation":"Initiation: 03/01/2015","start_date":" 03/01/2015","primary_txt":" Primary completion: 11/30/2020","primary_completion_date":" 11/30/2020","study_txt":" Completion: 11/30/2020","study_completion_date":" 11/30/2020","last_update_posted":"2021-05-14"},{"id":"ef305389-9686-430a-961c-050929e8a0a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT02807272","created_at":"2021-01-18T13:46:04.937Z","updated_at":"2024-07-02T16:36:30.264Z","phase":"Phase 2","brief_title":"Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid Leukemia","source_id_and_acronym":"NCT02807272","lead_sponsor":"Kura Oncology, Inc.","biomarkers":" KRAS • NRAS • CXCR4 • CXCR2","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type • NRAS wild-type • CXCR4 expression","tags":["KRAS • NRAS • CXCR4 • CXCR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type • NRAS wild-type • CXCR4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zarnestra (tipifarnib)"],"overall_status":"Completed","enrollment":" Enrollment 45","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 12/14/2020","primary_completion_date":" 12/14/2020","study_txt":" Completion: 12/14/2020","study_completion_date":" 12/14/2020","last_update_posted":"2021-05-14"},{"id":"541b6e15-f680-4fed-875c-89d65027c712","acronym":"","url":"https://clinicaltrials.gov/study/NCT02464228","created_at":"2021-01-17T17:51:01.848Z","updated_at":"2024-07-02T16:36:31.197Z","phase":"Phase 2","brief_title":"Investigation of Tipifarnib in Treatment of Subjects With PTCL That Have Not Responded to Standard Therapy.","source_id_and_acronym":"NCT02464228","lead_sponsor":"Kura Oncology, Inc.","biomarkers":" ALK • CXCL12","pipe":" | ","alterations":" ALK positive • ALK negative","tags":["ALK • CXCL12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zarnestra (tipifarnib)"],"overall_status":"Completed","enrollment":" Enrollment 65","initiation":"Initiation: 10/08/2015","start_date":" 10/08/2015","primary_txt":" Primary completion: 03/24/2021","primary_completion_date":" 03/24/2021","study_txt":" Completion: 03/24/2021","study_completion_date":" 03/24/2021","last_update_posted":"2021-04-27"},{"id":"fd9fbd7f-ee3d-4043-9831-01acedf500b0","acronym":"","url":"https://clinicaltrials.gov/study/NCT00470301","created_at":"2021-01-18T01:40:22.121Z","updated_at":"2024-07-02T16:36:34.566Z","phase":"Phase 1/2","brief_title":"Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer","source_id_and_acronym":"NCT00470301","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative • PGR positive • PGR negative","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PGR positive • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • doxorubicin hydrochloride • cyclophosphamide • Zarnestra (tipifarnib) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 04/01/2007","start_date":" 04/01/2007","primary_txt":" Primary completion: 09/01/2013","primary_completion_date":" 09/01/2013","study_txt":" Completion: 09/01/2013","study_completion_date":" 09/01/2013","last_update_posted":"2021-02-16"},{"id":"834f7878-f144-4132-a7c5-5d5bcd1de5e0","acronym":"Keynote-559","url":"https://clinicaltrials.gov/study/NCT03168139","created_at":"2021-01-18T15:37:14.845Z","updated_at":"2025-02-25T16:06:18.896Z","phase":"Phase 1/2","brief_title":"Olaptesed (NOX-A12) Alone and in Combination With Pembrolizumab in Colorectal and Pancreatic Cancer","source_id_and_acronym":"NCT03168139 - Keynote-559","lead_sponsor":"TME Pharma AG","biomarkers":" CXCL12","pipe":"","alterations":" ","tags":["CXCL12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • olaptesed pegol (NOX-A12)"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 04/18/2017","start_date":" 04/18/2017","primary_txt":" Primary completion: 03/25/2020","primary_completion_date":" 03/25/2020","study_txt":" Completion: 03/25/2020","study_completion_date":" 03/25/2020","last_update_posted":"2020-07-08"},{"id":"8a8d1435-ca0f-4ed3-945a-9e674dc58043","acronym":"","url":"https://clinicaltrials.gov/study/NCT00082810","created_at":"2021-01-18T00:14:04.073Z","updated_at":"2024-07-02T16:37:05.650Z","phase":"Phase 2","brief_title":"Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer","source_id_and_acronym":"NCT00082810","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PGR","pipe":"","alterations":" ","tags":["PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • Zarnestra (tipifarnib)"],"overall_status":"Completed","enrollment":" Enrollment 33","initiation":"Initiation: 03/01/2004","start_date":" 03/01/2004","primary_txt":" Primary completion: 07/01/2008","primary_completion_date":" 07/01/2008","study_txt":" Completion: 09/01/2008","study_completion_date":" 09/01/2008","last_update_posted":"2018-11-01"},{"id":"61d3072d-b3e5-468f-b9bd-37180e632549","acronym":"","url":"https://clinicaltrials.gov/study/NCT00335764","created_at":"2021-01-18T01:09:35.900Z","updated_at":"2024-07-02T16:37:09.330Z","phase":"Phase 1/2","brief_title":"Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma","source_id_and_acronym":"NCT00335764","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • sorafenib • temsirolimus • Zarnestra (tipifarnib)"],"overall_status":"Completed","enrollment":" Enrollment 92","initiation":"Initiation: 04/01/2006","start_date":" 04/01/2006","primary_txt":" Primary completion: 02/01/2010","primary_completion_date":" 02/01/2010","study_txt":" Completion: 09/01/2012","study_completion_date":" 09/01/2012","last_update_posted":"2018-07-02"},{"id":"01a7c4c6-036a-451b-8238-01cffd6ac6b5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02210858","created_at":"2021-01-18T10:21:21.648Z","updated_at":"2024-07-02T16:37:10.333Z","phase":"Phase 1/2","brief_title":"Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders","source_id_and_acronym":"NCT02210858","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS • ABL1 • BCR","pipe":" | ","alterations":" KRAS mutation • RAS mutation","tags":["KRAS • ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zarnestra (tipifarnib)"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 05/01/2000","start_date":" 05/01/2000","primary_txt":" Primary completion: 11/12/2004","primary_completion_date":" 11/12/2004","study_txt":" Completion: 03/01/2017","study_completion_date":" 03/01/2017","last_update_posted":"2018-06-04"},{"id":"c61ee56b-8ad9-4c81-89b2-8429da8db63a","acronym":"","url":"https://clinicaltrials.gov/study/NCT00021541","created_at":"2021-01-17T23:57:48.574Z","updated_at":"2024-07-02T16:37:11.457Z","phase":"Phase 2","brief_title":"R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas","source_id_and_acronym":"NCT00021541","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NF1","pipe":"","alterations":" ","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zarnestra (tipifarnib)"],"overall_status":"Completed","enrollment":" Enrollment 62","initiation":"Initiation: 07/17/2001","start_date":" 07/17/2001","primary_txt":" Primary completion: 02/19/2009","primary_completion_date":" 02/19/2009","study_txt":" Completion: 02/19/2009","study_completion_date":" 02/19/2009","last_update_posted":"2018-04-17"},{"id":"8a095384-8795-49e2-975e-166b35eb9264","acronym":"","url":"https://clinicaltrials.gov/study/NCT00331591","created_at":"2021-01-18T01:08:40.620Z","updated_at":"2024-07-02T16:37:23.802Z","phase":"Phase 2","brief_title":"Response to Tipifarnib in Individuals With Large Granular Lymphocyte Leukemia","source_id_and_acronym":"NCT00331591","lead_sponsor":"Office of Rare Diseases (ORD)","biomarkers":" CD8 • B3GAT1","pipe":"","alterations":" ","tags":["CD8 • B3GAT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zarnestra (tipifarnib)"],"overall_status":"Completed","enrollment":" Enrollment 42","initiation":"Initiation: 05/01/2006","start_date":" 05/01/2006","primary_txt":" Primary completion: 05/01/2007","primary_completion_date":" 05/01/2007","study_txt":" Completion: 05/01/2007","study_completion_date":" 05/01/2007","last_update_posted":"2017-04-05"}]